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A B S T R A C T
Purpose: Analyze clinical and electrographic characteristics of patients with autoimmune epilepsy, and
evaluate the effect of early diagnosis and treatment on reduction of seizure frequency.
Methods: Observational retrospective case series, conducted using electronic medical data from two
teaching hospitals. Clinical data was collected from 2008 to 2013. Cases of new onset seizures were
selected based on the presence of laboratory evidence of autoimmunity.
Results: 34 hospitalized patients who presented predominantly due to seizures with concern for
autoimmune etiology were identiﬁed. Mean age of patients was 44.94 years and 64.7% were males.
Autoimmune antibodies were detected in 76.5% (26) of patients as follows: VGKc (8); NMDA-R (7); anti-
thyroid (5); GAD (4); GABAB (2). 22 patients had unilateral temporal lobe onset and 4 had bilateral
temporal lobe onset, while 8 had extra-temporal onset/multiple ictal foci. Median number of seizures
during initial prolonged vEEG monitoring was 8 (range 0–48); median number of anti-seizure
medications used was 2 (range 1–5). 9 patients had an underlying malignancy. 94.1% (32) patients
received immunomodulation, as follows: high dose corticosteroids (96.8%), plasmapheresis (62.5%), IVIG
(34.4%), rituximab (21.8%), mycophenolate (15.6%), cyclophosphamide (12.5%). 63.3% (19) participants
achieved 50% seizure reduction (Responder Rate) at ﬁrst clinic visit. Patients without malignancy had
better seizure control (p < 0.05). Time from symptom onset to diagnosis (p < 0.005) and symptom onset to
immunomodulation (p < 0.005) was signiﬁcantly lower among patients who achieved responder rate (RR).
Conclusion: This study highlights certain important clinical and electrographic aspects of autoimmune
epilepsy, and the signiﬁcance of early diagnosis and initiation of immunomodulatory therapy.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Autoimmune epilepsy is an under-recognized condition with-
out standardized management guidelines [1]. However, identify-
ing an underlying autoimmune etiology for epilepsy is critical,
as these patients may remain refractory to conventional anti-
seizure medications (ASM). A large population-based study
(n > 2,000,000) showed that patients with autoimmune disease
constituted 17.5% of patients with epilepsy, and that the presence
of an autoimmune disorder may contribute to a fourfold increased
risk of epilepsy [2]. It is reasonable to have a high index of suspicion
for autoimmune epilepsy in these patients [3]. Despite increased
recent research interest, no clear guidelines exist for the diagnosis* Corresponding author at: University of Texas Southwestern Medical Center,
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latory therapies, including steroids, intravenous immunoglobulin
(IVIG), cyclophosphamide, and rituximab have been utilized to
achieve seizure control in ASM-resistant patients [4].
Epilepsy is a recognized manifestation of autoimmune enceph-
alitis [5]. Autoantibodies associated with encephalitides, as well as
with epilepsy, include those directed against neuronal intracellular
antigens or neuronal cell surface antigens. Neuronal cell surface
antigens include voltage gated potassium channel complex
(VGKc), NMDA and AMPA glutamate receptors, and GABA
receptors, whereas intra-neuronal autoantibodies include anti-
Hu, anti-Ma2, and anti-CRMP-5 [3,6,7]. Intraneuronal antibodies
have been shown to be a marker of underlying malignancy [8].
Neuronal cell death associated with these antibodies has shown to
be T-cell mediated, rather than direct antibody-mediated as with
surface antigen-related autoimmunity [9–11].
Our study is a retrospective case series of 34 patients with
varied clinical and electrographic characteristics who wereserved.
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currently sparse literature characterizing autoimmune epilepsy
and its management.
We hypothesized that that early diagnosis, as well as early
treatment initiation, would lead to signiﬁcant reduction in seizure
frequency, as measured by responder rate (RR). Additionally we
also hypothesized that the patients with underlying malignancy
would respond less favorably to immunomodulatory therapy
compared to those without cancer.
2. Methods
We conducted a retrospective chart review using data from two
teaching hospitals primarily managing adult patients [Parkland
Memorial Hospital (PMH) and UT Southwestern University
Hospital (UTSW)]. Clinical data was collected from January 2008
through December 2013. Institutional Review Board approval and
site clearance from both sites were obtained. Patients were
screened by selecting charts with a primary diagnosis correspond-
ing to the ICD-9 code of encephalitis (323.0, 323.9) during the
hospital encounter. Cases included in the study were patients
presenting with new onset electrographic seizure activity, plus at
least two of the following: (1) CSF ﬁndings consistent with
inﬂammation (elevated CSF protein >50 and/or lymphocytic
pleocytosis), (2) brain MRI showing signal changes consistent
with limbic encephalitis, (3) autoimmune/paraneoplastic anti-
bodies in serum or CSF which have been associated with
autoimmune encephalitis in previous studies (any neuronal
nuclear/cytoplasmic antibody such as anti-Hu or anti-CRMP-5,
any neuronal membrane antibody including anti-VGKC, anti-
NMDA-R, anti-GABAB-R, anti-ganglionic AChR, or anti-glutamic
acid decarboxylase (GAD) antibody), (4) new onset seizure
responding to immunomodulatory therapies. Cases were excluded
if there was evidence of another identiﬁed cause of the patient’s
seizures: (1) Presence of CSF viral/bacterial/fungal antigens or
antibodies or DNA PCR which could explain underlying acute
inﬂammatory brain parenchymal changes, (2) Presence of meta-
bolic abnormalities which could have precipitated seizures (severe
renal or hepatic failure, malignant hypertension, severe hypo/
hyperglycemia), (3) Presence of brain structural lesions such as
stroke, tumor, traumatic lesions, heterotopias, mesial temporal
sclerosis, vascular malformation, abscess or infectious lesion
which could have precipitated the presenting seizures.
Cases selected based on inclusion and exclusion criteria that did
not have a pre-speciﬁed antibody were further divided based on
the presence or absence of high titers of thyroid peroxidase (TPO)
antibodies (>100 IU/ml). Anti-TPO antibody was not included in
the pre-speciﬁed inclusion criteria, due to lack of speciﬁcity of this
antibody for autoimmune encephalopathy [12].
Collection of patient health information, including epidemio-
logical and demographic variables [age, sex, race, location (county
hospital or university hospital), clinical presentation, symptoms,
duration of presentation to diagnosis, laboratory tests, cerebrospinal
ﬂuid (CSF) analysis, type of antibodies, electro-encephalography
(EEG) ﬁndings, imaging (MRI), immunosuppressive therapies used,
and neurological outcome] was performed by manual search of the
electronic medical record system at both institutions (PMH and
UTSW). A reduction of 50% seizure frequency was considered a
favorable clinical outcome, and was termed the ‘‘Responder Rate’’
(RR).
Categorical variables were analyzed using Chi Square. Assess-
ment of normative distribution of independent variables was
performed by Shapiro–Wilk test of normality. Normative data was
analyzed by independent t-test, and non-normative data was
analyzed using Mann–Whitney U test. Due to multiple compar-
isons, Bonferroni correction was utilized; p-value of < 0.05 wasconsidered statistically signiﬁcant. Binomial logistic regression
was utilized to adjust for baseline characteristics.
3. Results
34 patients with autoimmune epilepsy were identiﬁed. Table 1
summarizes demographics and results. Mean age of patients was
44.94 years and 64.7% (22) of the patients were males. 52.9% (18)
cases came from the county hospital while 47.1% (16) came from
the university hospital. Speciﬁc autoimmune antibodies were
detected in 76.5% (26) of patients; anti-VGKc in 23.5% (8); anti-
NMDA-R in 20.6% (7); anti-thyroid/TPO in 14.7% (5); anti-GAD in
11.8% (4); anti-GABAB in 5.9% (2). Nine patients (26.5%) included in
the study had an underlying malignancy; 2 ovarian teratomas, 2
breast cancer, 1 adenocarcinoma of the lung, 1 small cell lung cancer,
1 testicular cancer, 1 papillary thyroid cancer and 1 thymoma.
Median duration of symptom onset to EEG was 22 days (3–96 days),
symptom onset to diagnosis was 32 days (5–393 days), symptom
onset to brain MRI brain was 33 days (2–309 days), and symptom
onset to immunomodulatory therapy initiation was 35 days (range
8–396 days). Median time to clinic follow-up after hospital
discharge was 53.5 days (19–101 days). Electrographic seizures
were documented in 64.7% (22) of patients in our institution, while
the remainder of the patients had evidence of electrographic
seizures at an outside hospital prior to transfer to our institution. Of
the 34 patients included, 22 (64.7%) had unilateral and 4 (11.8%) had
bilateral temporal lobe onset, while 8 (23.5%) had extra-temporal
onset/multiple ictal foci. 29.4% (10) patients had only electrographic
seizures, without clinical correlate; 44.1% (15) patients were
discovered to have focal status epilepticus on vEEG monitoring.
Interictal discharges were present in 79.4% (27) of cases. Median
number of seizures during initial prolonged vEEG monitoring was 8
(range 0–48); median number of anti-seizure medications used was
2 (range 1–5). 70.6% (24) patients had MRI changes concerning for
autoimmune encephalitis (Fig. 1).
63.3% (19) of patients had 50% reduction in seizure frequency
(RR) at the ﬁrst clinic visit, following inpatient management of
acute episode. 6 (17.6%) patients had complete resolution of
seizures on initial clinic follow up. 94.1% (32) patients received
immunomodulatory therapies, including high dose corticosteroids
(96.8%), plasmapheresis (62.5%), and IVIG (34.4%). 9 (28.1%)
patients received only high dose corticosteroids as immunomod-
ulatory therapy for acute management of recurrent seizures,
whereas the remaining patients received a combination of
corticosteroids with plasmapheresis and/or IVIG [Corticoster-
oids + plasmapheresis: 12(35.3%), Corticosteroids + IVIG + plasma-
pheresis: 8 (25%), Corticosteroids + IVIG 3 (9.4%)]. Several patients
also received additional immunomodulation in the form of
chemotherapeutic agents, including rituximab (21.8%), mycophe-
nolate (15.6%), cyclophosphamide (12.5%). There was no signiﬁ-
cant difference in RR at ﬁrst clinic visit with use of different
immunomodulatory regimens.
Among the two patients who did not receive immunomodula-
tion, one patient was started on levtriacetam 500 mg BID with
good seizure control; his evaluation was remarkable for CSF
pleocytosis and FLAIR hyperintesity involving left medial temporal
lobe, but no antibody was indentiﬁed. The second patient had anti-
GAD antibody, and also showed signiﬁcant improvement in seizure
frequency following initiation of levtriacetam.
There was no signiﬁcant difference in seizure reduction based
on gender, race, age, hospital category (county or university
hospital), presenting symptom (behavior change, memory loss,
seizure, altered mental status, speech changes, or movement
disorder), or type of antibody detected. But, patients without an
underlying malignancy had a better RR (p < 0.05). Having
antibodies directed against neuronal cell membrane antigens
Table 1
Demographic, clinical, imaging, and electroencephalographic characteristics, and 50% response rate of patients by antibody type.
Antibody Cases Age
(years)
Sex Race Malig. Initial symptom MRI
pattern
Electrographic
seizure onset
Mean
AEDs
FNCSE RR
VGKc 8 56 M 7 CA 5 3 (Breast Ca,
thymoma,
lymphoma)
Seizures (25%);
speech changes
(12.5%); altered
mentation (12.5%)
NL 0 UT 6 2.00
(SD 1.00)
2 5 (62.5%)
F 1 AA 2 UT 4 BT 1
HP 1 BT 2 ET 1
OT 0 ET 1
NMDA 7 29 M 4 CA 3 2 (Ovarian
teratoma)
Seizures (28.6%);
altered mentation
(14.3%)
NL 5 UT 5 2.00
(SD 1.00)
2 3 (42.9%)
F 3 AA 1 UT 1 BT 1
HP 3 BT 0 ET 1
OT 0 ET 1
GAD 4 50 M 1 CA 3 1 (Prostrate Ca) Memory loss
(33.3%), movement
disorder (16.7%)
NL 2 UT 2 1.00
(SD 4.00)
2 2 (50%)
F 3 AA 1 UT 0 BT 2
HP 0 BT 2 ET 0
OT 0 ET 0
GABAB 2 37 M 1 CA 1 1 (SCC lung) Seizures (100%) NL 0 UT 1 4.00
(SD 0.00)
2 1 (50%)
F 1 AA 0 UT 1 BT 0
HP 1 BT 0 ET 1
OT 0 ET 1
Anti-thyroid 5 55 M 3 CA 4 0 Seizures (20%);
movement
disorder (20%)
NL 2 UT 2 2.00
(SD 1.00)
3 2 (40%)
F 2 AA 1 UT 1 BT 0
HP 0 BT 0 ET 3
OT 0 ET 2
None 8 42 M 6 CA 4 2 (Testicular Ca,
ADCA lung)
Seizures
(62.5%); altered
mentation (12.5%)
NL 1 UT 6 3.00
(SD 1.00)
4 5 (62.5%)
F 2 AA 1 UT 4 BT 0
HP 1 BT 2 ET 2
OT 2 ET 1
VGKc, voltage gated potassium channel antibody; NMDA, N-methyl-D-aspartate receptor antibody; GAD, glutamic acid decarboxylase receptor antibody; GABAB, g-
aminobutyric acid B receptor antibody; M, Male; F, Female; CA, Caucasian; AA, African American; HP, Hispanic; OT, Other; Malig., presence of underlying malignancy; Ca,
Cancer; ADCA, Adenocarcinoma; SCC, small cell cancer; NL, Normal; UT, unilateral temporal; BT, bilateral temporal; ET, extra-temporal; AEDs anti-epileptic drugs; FNCSE,
focal non-convulsive status epilepticus; RR, 50% seizure reduction in response to therapy.
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signiﬁcantly. Duration of symptom onset to diagnosis (median
duration: 16 days versus 95 days, U = 48.00, p < 0.005) and
duration of symptom onset to immunomodulatory therapy
(median duration: 19 days versus 100.5 days, U = 43.00,
p < 0.005) was also signiﬁcantly lower among patients who had
50% reduction of seizures. Time from symptom onset to EEG
(U = 56.00, p < 0.05), symptom onset to Lumbar Puncture
(U = 56.50, p < 0.05) and symptom onset to MRI (U = 41.00,
p < 0.005) was signiﬁcantly lower among patients who had a
favorable Responder Rate. Even after adjustment of baseline
characteristics (age, gender, race, type of antibody), the time from
symptom onset to diagnosis (CI 0.82–0.98, p < 0.05) and time from
symptom onset to immunomodulation (CI 0.83–0.99, p < 0.05)
continued to be signiﬁcantly lower in the group with a favorable
Responder Rate. There was no signiﬁcant relationship between
average pre-treatment seizure frequencies or number of AEDs
used, or other clinical measures (CSF pleocytosis, interictal
discharges or ictal EEG pattern, or pattern of MRI changes) and RR.
4. Discussion
Our study supports the value of early diagnosis and immuno-
modulation in reducing seizure frequency in patients withautoimmune epilepsy, who are often resistant to conventional
ASM. In some of these refractory epilepsies, identiﬁcation of an
underlying auto-immune etiology and initiation of immunomo-
dulation might ultimately prevent unnecessary surgical interven-
tion. Additionally, we also found that patients with autoimmune
epilepsy without underlying malignancy are more likely to
experience seizure reduction with therapy. Prevalence of autoim-
mune epilepsy secondary to neuronal cell surface antigen speciﬁc
antibodies appears to be signiﬁcantly higher than intra-neuronal
antigen speciﬁc antibodies (typical paraneoplastic antibodies).
Our work builds on a similar recent study [3]. Quek et al.
published a retrospective observational case series of 32 patients
with autoimmune epilepsy, the majority of whom had VGKc
autoantibodies. The clinical characteristics of our study population
differed from theirs somewhat, as our two largest antibody
subgroups included VGKc and NMDA-R. We also compared these
two subgroups in regards to clinical, electrographic features and
clinical outcome but found no signiﬁcant difference. The most
common presenting symptom in our patients was seizure, as in
theirs. None of our cases underwent epilepsy surgery, though
several patients in their study did.
Quek et al. suggested some general diagnostic characteristics
that increase clinical suspicion for autoimmune epilepsy, which
are here conﬁrmed by our study, including high seizure frequency
Fig. 1. (A–F) 42 year female with VGKc antibody: MRI showing bilateral temporal FLAIR hyperintensities (A); 43 year male with VGKc antibody; MRI showing multifocal FLAIR
abnormalities (B); 53 year male with GABAB receptor antibody: MRI depicting right medial temporal FLAIR hyperintensity (C); 32 year male with no detectable underlying
paraneoplastic/autoimmune antibody: MRI depicting bilateral medial temporal FLAIR hyperintensities (D); 26 year female with NMDA-R antibody: MRI depicting frontal lobe
FLAIR hyperintensities (E,F).
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malignancy. Most of the antibody mediated encephalitides are
associated with temporal lobe epilepsy, while antibodies to
Leucine-rich, glioma inactivated 1 (LGI-1), a VGKc component,
may be associated with a facio-brachial dystonic seizure syndrome
[3,7,13]. Only one out of eight VGKc positive patients in our study
had faciobrachial dystonic seizures. The majority of our patients
had unilateral temporal lobe focus of epilepsy. Though previous
studies have documented EEG ﬁndings such as ‘extreme delta
brush’ in patients with NMDA-R antibody mediated encephalitis,
no antibody speciﬁc inter-ictal changes were found among our
patients [14]. Some patients have clinical, electrographic, radio-
graphic, and CSF characteristics consistent with autoimmune
epilepsy, even without underlying antibody positivity, which may
reﬂect the yet undiscovered array of neuronal antibodies that
could result in autoimmune epilepsy. Clinicians should, therefore,
consider the diagnosis of autoimmune epilepsy even if the CSF or
serum antibody panel is negative, based on the overall clinical
presentations including the EEG, MRI, CSF and other laboratory
ﬁndings [15,16].
To manage autoimmune epilepsy, Bien et al. have suggested
treating any underlying malignancy, then proceeding with IV
corticosteroid initiation (methylprednisolone), followed by cyclo-
phosphamide or rituximab if the epilepsy syndrome proves to be
resistant [17]. Even though the immunomodulatory regimen
varied in the patients included in our study, the majority of the
patients received IV corticosteroids as the initial therapy followed
by plasmapheresis or IVIG. In our study, only those patients who
remained refractory to corticosteroids or plasmapharesis or bothmodalities, received chemotherapeutic agents such as rituximab or
cyclophosphamide. Nevertheless, our study demonstrates that
early initiation of treatment leads to better overall RR, a common
marker of the success of antiepileptic treatment.
Limitations of this study include the retrospective design and
the small study population. Limited numbers made it difﬁcult to
assess statistical signiﬁcance in some variable associations.
Despite a thorough search of electronic medical records, some
autoimmune epilepsy patients could have been missed, especially
if coding or chart diagnosis was not correctly performed. Since only
9 patients underwent PET scans in our study, underlying
malignancy could have been missed. For twelve patients included
in our study no electrographic seizures were recorded in our
institution (PMH or UTSW), data collection was based on EEG
reports and medical records from out-side facility.
5. Conclusion
This study highlights important clinical aspects of autoimmune
epilepsy. Early diagnosis is likely the most critical step for affected
individuals, and the identiﬁcation of the common clinical and
electrographic presentations provided herein may aid in that
diagnosis. Furthermore, our study demonstrates that timely
initiation of immunomodulatory agents helps reduce seizure
frequency and that the patients without an underlying malignancy
tend to respond better to such therapy. Future prospective studies
will be necessary to determine the ideal immunomodulatory
treatment regimen for patients based on clinical presentation and
antibody-type.
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